Drugs & Targets EC expands approval of Reblozyl to first-line treatment of anemia in MDS April 12, 2024Vol.50 No.15
Drugs & Targets Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors April 05, 2024Vol.50 No.14
Drugs & Targets Scripius and Avera collaborate to reduce prescription costs April 05, 2024Vol.50 No.14
Drugs & Targets FDA approves Elahere for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer March 29, 2024Vol.50 No.13
Drugs & Targets FDA grants orphan drug designation to Heidelberg Pharma agent for MM March 29, 2024Vol.50 No.13
Drugs & Targets FDA grants accelerated approval to Iclusig + chemotherapy for newly diagnosed Ph+ ALL March 22, 2024Vol.50 No.12
Drugs & Targets FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products March 22, 2024Vol.50 No.12
Drugs & Targets The Jackson Laboratory, LG AI Research partner to use AI to diagnose and treat cancer, Alzheimer’s March 22, 2024Vol.50 No.12
Drugs & Targets Tempus contributes de-identified cancer data to NCI’s planned data enclave March 22, 2024Vol.50 No.12
